Prognostic accuracy of frailty & vulnerability screening in older ED patients: a systematic review & meta-analysis
Abstract
Abstract Frailty is associated with increased mortality and morbidity in older adults, highlighting the need for effective screening in emergency departments (EDs). However, the optimal tool for predicting adverse outcomes remains uncertain. Therefore, our review’s question is: which frailty and vulnerability screening instrument has the highest prognostic accuracy for adverse outcomes in older adults visiting EDs? Studies were eligible for inclusion if they included patients aged ≥60 admitted to the ED, used frailty or vulnerability instruments, and reported sensitivity, specificity, and area under the curve (AUC). Databases searched until January 25, 2025, included MEDLINE, EMBASE, Cochrane Library, CINAHL, and CNKI. Study quality was assessed using the updated Quality in Prognosis Studies (QUIPS) tool. Two investigators independently reviewed abstracts and full-texts. A meta-analysis was conducted for tools with consistent cutoffs in ≥ 4 studies. Sixty-seven papers described 62 studies using 40 screening instruments. The Identification of Seniors at Risk (ISAR) was the most frequently used (n = 25), followed by the Clinical Frailty Scale (CFS) (n = 15) and the Triage Risk Screening Tool (TRST)(n = 11). Most instruments showed high sensitivity but low specificity. Meta-analysis was feasible for ISAR and TRST. ISAR’s pooled sensitivity, specificity, and AUC for in-hospital mortality were 92% (95% CI, 88-95), 26% (95% CI, 21-33), and 0.82. For ED revisits, ISAR’s AUC was…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 25 participants or records.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.